SCHEMBL5855147

SCHEMBL5855147

CC(=O)C(CCCCCCOC(C)(C)C(=O)O)NC(=O)c1ccc(C(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 3/20 0.41
RAB9A P51151 3/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
TGM2 P21980 1/20 0.38
PRSS1 P07477 2/20 0.38
CTSG P08311 2/20 0.38
CTRB1 P17538 2/20 0.38
CMA1 P23946 2/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC3 O15379 2/20 0.38
HDAC2 Q92769 2/20 0.38
PPARG P37231 2/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38
LMNA P02545 1/20 0.37
CA2 P00918 1/20 0.37
CA12 O43570 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5858508 0.92 TGM2 (0.45) NR1H4RAB9ANPC1POLBCASP3
SCHEMBL5857551 0.91 PPARG (0.40) PRSS1CTSGCTRB1CMA1HDAC1
SCHEMBL5855307 0.91 PRSS1 (0.46) PRSS1CTSGCTRB1CMA1HDAC1
SCHEMBL5855621 0.91 PRSS1 (0.46) PRSS1CTSGCTRB1CMA1HDAC1
SCHEMBL5855899 0.91 PRSS1 (0.46) PRSS1CTSGCTRB1CMA1HDAC1
SCHEMBL5857667 0.90 CTSL (0.44) NPC1PRSS1CTSGCTRB1CMA1
SCHEMBL5858331 0.90 PSEN1 (0.43) POLBPPARGPPARDPPARALMNA
SCHEMBL5855798 0.90 MAPT (0.38) NR1H4RAB9ANPC1POLBCASP3
SCHEMBL5857654 0.83 ALB (0.46) TGM2PPARGPPARDPPARACA2
SCHEMBL5857630 0.82 ITGB3 (0.47) PRSS1CTSGCTRB1CMA1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB NR1H4 479/4885RAB9A 3996/4885NPC1 32/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE NR1H4 612/4885RAB9A 3631/4885NPC1 40/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC NR1H4 597/4885RAB9A 3492/4885NPC1 63/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC NR1H4 597/4885RAB9A 3492/4885NPC1 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.